BlackRock Posts Mixed Q3 Earnings; Bullish View On Immunovant
- October 13th, 2023
- 465 views
BlackRock, Inc. (NYSE: BLK), an investment management and financial services company, reported third-quarter 2023 adjusted earnings per share (EPS) of $10.91, surpassing the consensus EPS estimate of $8.26. However, the company's revenue for the period stood at $4.522 billion, slightly below analysts' expectations of $4.54 billion.
$BLK was trading at $630.00 in pre-market, reflecting a decrease of $6.17 (-0.97%).
In other news, UBS has upgraded Immunovant, Inc. (Nasdaq: IMVT), a biopharmaceutical company, from Neutral to Buy and raised the price target from $18 to $55.
Despite closing at $35.28 on Thursday, the adjusted price target indicates a potential upside of $19.72 or about 55.86% for $IMVT, based on the financial services firm's analysis
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Earnings Preview: Walt Disney, Applied Materials, and Celcuity Take Center Stage
November 11th, 2024Key Metrics: CyberArk Software, Hudbay Minerals, and Sonos Earnings Due
November 11th, 2024Earnings: What to Expect from Occidental Petroleum, Rocket Lab, and CAE
November 10th, 2024Earnings Countdown: Home Depot, Sea Limited, and Natera in the Spotlight
November 10th, 2024Ahead of Earnings: DoorDash, MetLife, and Exelon in the Spotlight
October 27th, 2024
Member Login